863 related articles for article (PubMed ID: 24758886)
21. Progress in the pharmacotherapy of gout.
Sundy JS
Curr Opin Rheumatol; 2010 Mar; 22(2):188-93. PubMed ID: 20110792
[TBL] [Abstract][Full Text] [Related]
22. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
Keenan RT
Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
[TBL] [Abstract][Full Text] [Related]
23. Hyperuricaemia and gout.
Shipley M
J R Coll Physicians Edinb; 2011 Sep; 41(3):229-33. PubMed ID: 21949921
[TBL] [Abstract][Full Text] [Related]
24. Gout: nonsteroidal anti-inflammatory drugs and colchicine to prevent painful flares during early urate-lowering therapy.
Kuritzky L; Panchal R
J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):397-401. PubMed ID: 21133750
[TBL] [Abstract][Full Text] [Related]
25. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of a urate lowering regimen in primary gout.
Bailén R; González Senac NM; López MM; Llena ML; Migoya M; Rodríguez MT; de Miguel E; Torres RJ; Puig JG
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):174-80. PubMed ID: 24940666
[TBL] [Abstract][Full Text] [Related]
27. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
28. Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.
Robinson PC; Horsburgh S
Maturitas; 2014 Aug; 78(4):245-51. PubMed ID: 24880206
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis, treatment, and prevention of gout.
Hainer BL; Matheson E; Wilkes RT
Am Fam Physician; 2014 Dec; 90(12):831-6. PubMed ID: 25591183
[TBL] [Abstract][Full Text] [Related]
30. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
Soskind R; Abazia DT; Bridgeman MB
Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic approaches in the treatment of gout.
Pillinger MH; Mandell BF
Semin Arthritis Rheum; 2020 Jun; 50(3S):S24-S30. PubMed ID: 32620199
[TBL] [Abstract][Full Text] [Related]
32. Expert opinion on emerging urate-lowering therapies.
Stamp LK; Merriman TR; Singh JA
Expert Opin Emerg Drugs; 2018 Sep; 23(3):201-209. PubMed ID: 30244605
[TBL] [Abstract][Full Text] [Related]
33. A new perspective on the pharmacoeconomics of colchicine.
Wertheimer AI; Davis MW; Lauterio TJ
Curr Med Res Opin; 2011 May; 27(5):931-7. PubMed ID: 21370937
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
35. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
36. Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB; Neogi T
Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
[TBL] [Abstract][Full Text] [Related]
37. Gout.
Dalbeth N; Choi HK; Joosten LAB; Khanna PP; Matsuo H; Perez-Ruiz F; Stamp LK
Nat Rev Dis Primers; 2019 Sep; 5(1):69. PubMed ID: 31558729
[TBL] [Abstract][Full Text] [Related]
38. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
